Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from CERo Therapeutics Holdings ( (CERO) ) is now available.
On October 29, 2025, CERo Therapeutics Holdings announced that its request to continue listing its common stock on Nasdaq was denied by the Nasdaq Hearings Panel due to non-compliance with the minimum stockholders’ equity requirement. Consequently, trading of its shares on Nasdaq will be suspended starting October 31, 2025. The company is exploring alternatives, including trading on the OTC Markets and other securities exchanges, while continuing its clinical trials and reviewing financing options to support operations. The suspension could adversely affect stock trading price and volume, impacting stakeholders.
The most recent analyst rating on (CERO) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. is an innovative immunotherapy company focused on developing next-generation engineered T cell therapeutics for cancer treatment. The company’s proprietary approach integrates innate and adaptive immunity within a single therapeutic construct, targeting tumor cells through adaptive perforin/granzyme pathways and innate engulfment mechanisms. CERo’s lead product candidate, CER-1236, is in clinical trials for hematologic malignancies.
Average Trading Volume: 259,674
Technical Sentiment Signal: Sell
Current Market Cap: $2.16M
For a thorough assessment of CERO stock, go to TipRanks’ Stock Analysis page.